Work

Abstract CT041: Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct041

Authors: Jason T. Henry, Manish R. Patel, Paul Swiecicki, Ida Micaily, Benjamin Garmezy, Kalyan Banda, Marya Chaney, Julia Cohen, Vinny Hayreh, Evan Y. Yu, Shawn P. Iadonato, Thierry Guillaudeux, Lee Rosen

Institutions: HealthONE, University of Michigan, Thomas Jefferson University, Sarah Cannon, Fred Hutch Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Kineta (United States), University of California, Los Angeles

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822302

Cites:

Cited by: 1

Related to: 10